Literature DB >> 12170243

Clinical and laboratory-based methods in the diagnosis of natural rubber latex allergy.

Robert G Hamilton1, Edward L Peterson, Dennis R Ownby.   

Abstract

The accurate diagnosis of hypersensitivity to natural rubber latex is the initial step in the effective management of individuals with latex allergy and in ensuring the quality of epidemiologic studies. The diagnostic algorithm used in the evaluation of an individual with suspected latex allergy begins with a comprehensive clinical history during which risk factors (atopy, food allergies, hand dermatitis) and temporal relationships between symptoms and natural rubber product exposure are identified. If type IV hypersensitivity is suspected because of the delayed nature (hours to days) and confinement of symptoms to the skin-latex product contact areas, patch testing can be conducted to confirm the presence of activated T cells with specificity for rubber chemicals. If type I hypersensitivity is suspected because of ocular, upper and lower airway, and/or systemic symptoms that have rapid onset (minutes) after a definable latex exposure, a confirmatory skin or blood test for IgE antibody may be conducted to verify a state of sensitization within the individual. The definitive diagnosis would then be made only after consideration of the individual's clinical history and confirmatory in vivo and/or in vitro laboratory test results. If discordance remains between highly convincing latex-associated symptoms as identified in the history and repetitively negative confirmatory IgE antibody test results, then one of several types of in vivo provocation tests may be performed for adjudication. This overview examines the current state of the art in both in vivo and in vitro diagnostic methods for latex-specific IgE antibody detection in skin and blood. The performance, advantages, and limitations of each diagnostic method are compared.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170243     DOI: 10.1067/mai.2002.125334

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

Review 1.  Prevention of anaphylactic reactions to anaesthetic drugs.

Authors:  Malcolm M Fisher; Gordon S Doig
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Diagnostic value of the ISAC(®) allergy chip in detecting latex sensitizations.

Authors:  Florian Seyfarth; Sibylle Schliemann; Cornelia Wiegand; Uta-Christina Hipler; Peter Elsner
Journal:  Int Arch Occup Environ Health       Date:  2013-12-06       Impact factor: 3.015

3.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

Review 4.  Anaphylaxis avoidance and management: educating patients and their caregivers.

Authors:  Kirsi M Järvinen; Jocelyn Celestin
Journal:  J Asthma Allergy       Date:  2014-07-10

5.  LATEX sensitization in elderly: allergological study and diagnostic protocol.

Authors:  Teresa Grieco; Valentina Faina; Laura Dies; Marzio Milana; Emidio Silvestri; Stefano Calvieri
Journal:  Immun Ageing       Date:  2014-05-02       Impact factor: 6.400

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.